Clinical Trial

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Study acronym: CABOLD
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT06934057
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: Ipsen
Conditions Kidney Cancer, Renal Cell Cancer
Enrollment 50 participants
Start Date 2025-05-16
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-09-24